Plus ça change ⋯ antiretroviral therapy, HIV prevention, and the HIV treatment cascade

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 1012-1014

  De Cock, Kevin M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Care; continuum; Cascade; HIV; Treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; DISEASE COURSE; DISEASE TRANSMISSION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION PREVENTION; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; HIV INFECTIONS;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS;

EID: 84921765395     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu026     Document Type: Note

References (15)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2013. Available at: http://www.who. int/hiv/pub/guidelines/arv2013/en/index. html. Accessed 6 January 2014.
3. De Cock KM, El-Sadr WM. When to start ART in Africa - an urgent research priority. New Engl J Med 2013; 368:886-9.
4. McNairy ML, El-Sadr WM. Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis 2014; 58:1003-11.
5. Piot MA. A simulation model of case finding and treatment in tuberculosis control. Geneva, Switzerland: World Health Organization, 1967. Available at: WHO/TB/Techn. Information/67.53.WHO-TB-Techn-Infor mation-67.53-eng.pdf. Accessed 6 January 2014.
6. Hayes R, Wawer M, Gray R, Whitworth J, Grosskurth H, Mabey D; HIV/STD Trials Workshop Group. Randomised trials of STD treatment for HIV prevention: report of an international workshop. Genitourin Med 1997; 73:432-43.
7. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Arch Intern Med 1994; 154: 1971-6.
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-80.
9. Janssen RS, Holtgrave DR, Valdiserri DO, ShepherdM,GayleDH,DeCockKM.The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health 2001; 91:1019-24.
10. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
11. Montaner SG, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-9.
12. Das M, Lee Chu P, Santos G-M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5: e11068.
13. Miller WC, Powers KA, Smith MK, Cohen MS. Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis 2013; 13:459-64.
14. National AIDS and STI Control Programme, Ministry of Health, Kenya. Kenya AIDS Indicator Survey 2012: preliminary report. Nairobi, Kenya: Ministry of Health, 2013.
15. De Cock KM, Marum E, Mbori-Ngacha D. A serostatus-based approach to HIV/AIDS prevention and care in Africa. Lancet 2003; 362: 1847-9.